Atai: Following the path that Spravato laid and moving beyond it
Feb 27, 2025•33 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Pursuing social anxiety disorder with MDMA. Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds (1:30). Standing on the shoulders of Johnson & Johnson's Spravato (4:00). Upcoming milestones and clinical trials (13:15). Psychedelic industry sentiment; RFK Jr influence (30:40).
Show Notes:
Psychedelic Stocks: Focus On Their Cash
Deep Dive: Atai Life Sciences
FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks Unchanged
Read our episode transcripts
For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
Show Notes:
Psychedelic Stocks: Focus On Their Cash
Deep Dive: Atai Life Sciences
FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks Unchanged
Read our episode transcripts
For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
For the best experience, listen in Metacast app for iOS or Android